Useful Resources

What are Advanced Therapies Medicinal Products (ATMPs)?

  • Advanced Therapy Medicinal Products: Overview

  • Briefing Session

    Gene Therapies: Transforming the lives of patients today – Bakhuti Shengelia (Novartis)

  • Briefing Session

    The value of cell and gene therapies for patients and healthcare systems – Avril Daly (Retina International)

  • Briefing Session

    Understanding the promise of cell and gene therapies – Prof. Francesco Muntoni (UCL)

The Lifecycle of ATMPs: from Early Diagnosis to Access to Patients

  • How can we maximise the value of cell and gene therapies through early detection?
  • Briefing Session

    Introductions by MEP Pietikäinen & MEP Kympouropoulos

    Speakers:

    MEP Sirpa Pietikainen (EPP, FI)

    MEP Stelios Kympouropoulos (EPP, GR)

    Victor Maertens, Government Affairs Manager, EUCOPE

    Read more ↓
  • Briefing Session

    Martine Pergent (IPOPI)

  • Briefing Session

    Tim Wilsdon (CRA)

  • How to make Europe more attractive for cell and gene therapy development?
  • Briefing Session

    Introductions by MEP Pernille Weiss (EPP, DK), MEP Radka Maxova (S&D, CZ) and Victor Maertens (EUCOPE)

    Module 6: How to make Europe more attractive for gene and cell therapy development?

    • MEP Pernille Weiss (EPP, DK)
    • MEP Radka Maxova (S&D, CZ)
    • Victor Maertens (Government Affairs Manager, EUCOPE)
    Read more ↓
  • Briefing Session

    Christina Kyriakopoulou (DG RTD)

  • Briefing Session

    Adam Hutchings (Dolon)

  • Briefing Session

    Frédéric Druck (essencia/bio.be)

  • How are cell and gene therapies manufactured?
  • Briefing Session

    Brid Carberry (Novartis)

  • Gene Therapy Manufacturing – PTC Centre of Excellence

  • Gene & cell therapy regulation and what it means for the revision of the pharmaceutical legislation?
  • Briefing Session

    Introduction by Alexander Natz (EUCOPE)

  • Briefing Session

    Martina Schussler-Lenz (EMA Committee for Advanced Therapies, Paul-Ehrlich Institute)

  • Briefing Session

    Simone Boselli (EURORDIS)

  • Towards better use and exchange of Real-World Evidence for cell and gene therapies
  • Briefing Session

    Introduction by MEP Susana Solis, MEP Manuel Pizarro & Victor Maertens (EUCOPE)

  • Briefing Session

    Elke Grooten (Novartis)

  • Briefing Session

    Guillaume Byk (DG SANTE)

  • Briefing Session

    Jo De Cock (INAMI-RIZIV)

  • Briefing Session

    Alessandra Ferlini (Medical Geneticist & Neurologist, ERN representative)

Literature

  • Event Report

    INAMI (2019), Innovative funding solutions for paradigm changing advanced therapy medicinal products (ATMP) in Belgium

  • Academic Article

    van Overbeeke et al (2020), Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions

  • Academic Article

    Reineke et al (2022), Market access to new anticancer medicines for children and adolescents with cancer in Europe

  • Academic Article

    Gene therapy in the putamen for curing AADC deficiency and Parkinson’s disease

European Gene and Cell Therapy Database

  • European Gene and Cell Therapy Database